Avidity Biosciences Inc

RNA is in a Stage 2 advancing corrective reset range with short‐term EMAs now acting as support. The medium‐term bias remains bullish anchored by the longer‐term uptrend, but short‐term timing is neutral. We will patient wait for pullbacks into the EMAs around the lower bound of the range to establish a structured entry opportunity rather than executing immediately.

• ↑FDA cleared ATR 1072 IND on July 29 2026, enabling Phase 1/2 trial.
• ↑$12 B deal adds three late-stage assets, boosting multi-billion dollar pipeline.
• ↓Negative earnings yield and low profitability hinder return potential.